Physician profile
Molly Scheich
NPI 1912352139
$731.90
in general payments reported to CMS, 2019-2025
21 companies · $75.77 in 2025
The $75.77 reported for 2025 was less than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $67.53 · 2022: $156 · 2023: $225 · 2024: $208 · 2025: $75.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $508.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $105.25 | 2023-2025 | |
| Ucb, INC. | $87.16 | 2023-2024 | Fintepla, Briviact, Zilbrysq |
| Sientra, INC. | $57.02 | 2022 | |
| Biogen, INC. | $55.86 | 2021-2024 | Vumerity |
| Teva Pharmaceuticals USA, INC. | $55.73 | 2023-2024 | Austedo Xr |
| Eisai INC. | $44.32 | 2023-2024 | |
| Integra Lifesciences Corporation | $40.78 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Ani Pharmaceuticals, INC. | $31.75 | 2024 | Purified Cortrophin Gel |
| Genentech USA, INC. | $31.47 | 2021-2024 | Ocrevus |
| Banner Life Sciences, LLC | $27.73 | 2024 | |
| Upsher-Smith Laboratories LLC | $22.23 | 2021 | |
| Supernus Pharmaceuticals, INC. | $20.32 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $19.90 | 2022 | |
| Lilly USA, LLC | $19.58 | 2025 | Kisunla |
| Avion Pharmaceuticals | $18.16 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $17.65 | 2023 | Mavenclad |
| Azurity Pharmaceuticals, INC. | $16.68 | 2024 | Horizant |
| Csl Behring | $16.08 | 2023 | Hizentra |
| Kyowa Kirin, INC. | $15.21 | 2023 | Nourianz |
| Novartis Pharmaceuticals Corporation | $14.58 | 2022 | |
| Grt US Holding, INC. | $14.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Scheich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.